NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹212.00
- Market cap
- ₹235.7 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 24.4×Sector 42.0×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Investor Presentation: Key Takeaways
H1 FY27 revenue ₹55.04 Cr (+25.83% YoY), PAT ₹8.20 Cr (+72.63%), EBITDA margin 22.48%. Export share rose to 18.15%.
Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Other board meeting date announcements
All →Aravali Securities & Finance Board Meeting Date
Aravali Securities will hold a board meeting on November 13, 2026 to consider unaudited half-year results. The trading window stays closed until November 15, 2026.
Filatex Fashions Board Meeting Date
Filatex Fashions schedules a November 14, 2026 board meeting to consider unaudited Q2 and half-year results. Trading window stays closed until 48 hours after results release.
Munoth Financial Services Board Meeting Date
Munoth Financial Services will hold a board meeting on 13 November 2026 to consider unaudited standalone quarterly results for September 2026. Trading window is closed from 1 October to 16 November 2026.
Mobilise App Lab Board Meeting Date
Mobilise App Lab Limited will hold a board meeting on 12-Nov-2026 to consider unaudited standalone half-yearly results for September 2026. The trading window stays closed until 14-Nov-2026.
7Seas Entertainment Board Meeting Date
7Seas Entertainment schedules a November 13, 2026 board meeting to consider unaudited standalone half-year results ended September 2026. Trading window closed October 1 to November 15.
Munoth Communication Board Meeting Date
Munoth Communication schedules a November 13, 2026 board meeting for unaudited standalone September 2026 quarter results. Trading window closed October 1 to November 16, 2026.